Ranjan Tiwari

1.7k total citations
38 papers, 384 citations indexed

About

Ranjan Tiwari is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Ranjan Tiwari has authored 38 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Hematology and 10 papers in Genetics. Recurrent topics in Ranjan Tiwari's work include CAR-T cell therapy research (19 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Lymphoblastic Leukemia research (6 papers). Ranjan Tiwari is often cited by papers focused on CAR-T cell therapy research (19 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Lymphoblastic Leukemia research (6 papers). Ranjan Tiwari collaborates with scholars based in India, United States and Canada. Ranjan Tiwari's co-authors include Chandrakant Lahariya, Stephen J. Schuster, Lida Pacaud, Richard T. Maziarz, Haifa Kathrin Al‐Ali, Michael Bishop, Lynda Foltz, Peter Borchmann, Jason R. Westin and Edmund K. Waller and has published in prestigious journals such as Blood, Leukemia and Journal for ImmunoTherapy of Cancer.

In The Last Decade

Ranjan Tiwari

34 papers receiving 373 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ranjan Tiwari India	11	186	110	105	95	51	38	384
Muhammad Ashar Ali United States	9	73 0.4×	53 0.5×	55 0.5×	63 0.7×	7 0.1×	41	298
Lisa Wray United States	10	271 1.5×	14 0.1×	68 0.6×	61 0.6×	33 0.6×	22	398
Nosha Farhadfar United States	11	111 0.6×	52 0.5×	188 1.8×	67 0.7×	3 0.1×	49	318
Iwona Homa‐Mlak Poland	12	72 0.4×	10 0.1×	38 0.4×	64 0.7×	12 0.2×	37	289
Eneida R. Nemecek United States	14	161 0.9×	54 0.5×	404 3.8×	63 0.7×	11 0.2×	31	588
Minako Iida Japan	7	102 0.5×	78 0.7×	290 2.8×	80 0.8×		13	436
Eric S. Schafer United States	11	92 0.5×	33 0.3×	95 0.9×	115 1.2×	6 0.1×	36	391
Priyanka A. Pophali United States	9	101 0.5×	70 0.6×	164 1.6×	52 0.5×	3 0.1×	35	342
Lamis Eldjerou United States	10	178 1.0×	28 0.3×	65 0.6×	29 0.3×	25 0.5×	22	260
Suheil Albert Atallah‐Yunes United States	8	172 0.9×	34 0.3×	26 0.2×	42 0.4×	9 0.2×	22	305

Countries citing papers authored by Ranjan Tiwari

Since Specialization

Citations

This map shows the geographic impact of Ranjan Tiwari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ranjan Tiwari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ranjan Tiwari more than expected).

Fields of papers citing papers by Ranjan Tiwari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ranjan Tiwari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ranjan Tiwari. The network helps show where Ranjan Tiwari may publish in the future.

Co-authorship network of co-authors of Ranjan Tiwari

This figure shows the co-authorship network connecting the top 25 collaborators of Ranjan Tiwari. A scholar is included among the top collaborators of Ranjan Tiwari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ranjan Tiwari. Ranjan Tiwari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

John, Samuel, Kevin J. Curran, Amy K. Keating, et al.. (2025). Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Advances. 9(20). 5249–5262.

Landsburg, Daniel J., Matthew J. Frigault, S.R. Foley, et al.. (2025). Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. Journal for ImmunoTherapy of Cancer. 13(2). e009890–e009890. 3 indexed citations

Kato, Koji, Jun Kato, Hideki Goto, et al.. (2025). Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial. Cytotherapy. 27(8). 938–943.

Landsburg, Daniel J., Amy Moskop, S.R. Foley, et al.. (2024). Durable Efficacy and Manageable Safety in Patients Age ≥75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting. Transplantation and Cellular Therapy. 30(2). S187–S188.

Vijayakumar, M., et al.. (2024). Synthesis and evaluation of novel pyrimidine derivative targeting pancreatic adenocarcinoma. 7. 11–11.

Risitano, Antonio M., Bing Han, Austin Kulasekararaj, et al.. (2023). Categorization of Hematological Responses to Oral Iptacopan Monotherapy in Anti-C5-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia in the Phase III APPLY-PNH Trial and Complement Inhibitor-Naïve Patients in the Phase III APPOINT-PNH Trial. Blood. 142(Supplement 1). 4084–4084. 4 indexed citations

John, Samuel, Michael Heim, Kevin J. Curran, et al.. (2023). Improved Relapse-Free Survival (RFS) for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Low or Intermediate Preinfusion Disease Burden Treated with Tisagenlecleucel: Results from the CIBMTR Registry. Transplantation and Cellular Therapy. 29(2). S37–S38. 1 indexed citations

Tiwari, Ranjan, et al.. (2023). Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy. 29(9). 579.e1–579.e10. 4 indexed citations

Landsburg, Daniel J., Amy Moskop, S.R. Foley, et al.. (2023). Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting. Blood. 142(Supplement 1). 3496–3496. 2 indexed citations

10.

Fowler, Nathan, Michael Dickinson, Monalisa Ghosh, et al.. (2022). Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study. Transplantation and Cellular Therapy. 29(1). 60.e1–60.e4. 12 indexed citations

11.

Laetsch, Theodore W., Shannon L. Maude, Adriana Balduzzi, et al.. (2022). Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia. 36(6). 1508–1515. 26 indexed citations

12.

Passamonti, Francesco, Vikas Gupta, Bruno Martino, et al.. (2021). Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study. Hematological Oncology. 39(4). 558–566. 8 indexed citations

13.

Hughes, Timothy P., Nelma Cristina D. Clementino, Jeffrey H. Lipton, et al.. (2021). Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia. 35(6). 1631–1642. 26 indexed citations

14.

Fowler, Nathan, Michael Dickinson, Monalisa Ghosh, et al.. (2021). Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study. Blood. 138(Supplement 1). 3533–3533. 4 indexed citations

15.

John, Samuel, Michael A. Pulsipher, Amy Moskop, et al.. (2021). Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 138(Supplement 1). 428–428. 12 indexed citations

16.

Cervantes, Francisco, David M. Ross, Atanas Radinoff, et al.. (2021). Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia. 35(12). 3455–3465. 39 indexed citations

17.

Joshi, Arun, et al.. (2021). Plasma cell rich acute rejection: Risk factors, treatment and outcomes. Saudi Journal of Kidney Diseases and Transplantation. 32(2). 387–387. 1 indexed citations

18.

Tiwari, Ranjan, et al.. (2014). Evaluation of Preoperative Serum Levels of CA 125 and Expression of p53 in Ovarian Neoplasms: A Prospective Clinicopathological Study in a Tertiary Care Hospital. The Journal of Obstetrics and Gynecology of India. 66(2). 107–114. 6 indexed citations

19.

Tiwari, Ranjan, et al.. (2008). Nutritional assessment of patients under hemodialysis in nepal medical college teaching hospital.. PubMed. 10(3). 164–9. 6 indexed citations

20.

Tiwari, Ranjan, et al.. (2007). The Determinants of Exclusive Breast Feeding in Urban Slums: A Community Based Study. Journal of Tropical Pediatrics. 55(1). 49–54. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact